Minakem-flap
Minakem-flap

Find Drugs for Infections and Infectious Diseases in Phase I Clinical Development in CHINA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JMB-2002

            Therapeutic Area: Infections and Infectious Diseases Product Name: JMB-2002

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 20, 2021

            Details:

            Preclinical studies of JMB2002 including pharmacology and toxicity were carried out systemically. The drug metabolism, safety and efficacy were well performed. In early studies, it was found that JMB2002 could effectively neutralize live virus infection of Vero E6 cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 S-Trimer vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $328.0 million Upfront Cash: $69.5 million

            Deal Type: Funding November 03, 2020

            Details:

            Funding will support development of Clover’s protein-based S-Trimer vaccine candidate through to licensure, including a global pivotal Phase 2/3 efficacy clinical study beginning before the end of 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 S-Trimer vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 30, 2020

            Details:

            Clover is the second Chinese developer to apply for Phase 3 clinical trials in the Philippines following Sinovac Biotech, which is seeking to begin trials of its vaccine as early as next month.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 S-Trimer vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 25, 2020

            Details:

            Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animals and protects nonhuman primates from SARS-CoV-2 challenge.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JS016

            Therapeutic Area: Infections and Infectious Diseases Product Name: JS016

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 12, 2020

            Details:

            The study is a randomized, double-blind, placebo-controlled Phase I trial is intended to investigate the safety and tolerability of single dose JS016 intravenous injection (IV) in 40 healthy subjects.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): S-Trimer COVID vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: Undisclosed Upfront Cash: $66.0 million

            Deal Type: Funding July 08, 2020

            Details:

            Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year.